These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

308 related articles for article (PubMed ID: 35170259)

  • 1. A survey: Understanding the health and perspectives of people with CF not benefiting from CFTR modulators.
    Kramer-Golinkoff E; Camacho A; Kramer L; Taylor-Cousar JL
    Pediatr Pulmonol; 2022 May; 57(5):1253-1261. PubMed ID: 35170259
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CFTR Modulators: Current Status and Evolving Knowledge.
    Regard L; Martin C; Da Silva J; Burgel PR
    Semin Respir Crit Care Med; 2023 Apr; 44(2):186-195. PubMed ID: 36535667
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A grumbling concern: A survey of gastrointestinal symptoms in cystic fibrosis in the modulator era.
    Calthorpe RJ; Goodchild N; Gleetus V; Premakumar V; Hayee B; Elliott Z; Evans B; Rowbotham NJ; Carr SB; Barr H; Horsley A; Peckham D; Smyth AR
    NIHR Open Res; 2023; 3():18. PubMed ID: 37881465
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pseudomonas aeruginosa infection, but not mono or dual-combination CFTR modulator therapy affects circulating regulatory T cells in an adult population with cystic fibrosis.
    Westhölter D; Beckert H; Straßburg S; Welsner M; Sutharsan S; Taube C; Reuter S
    J Cyst Fibros; 2021 Nov; 20(6):1072-1079. PubMed ID: 34030985
    [TBL] [Abstract][Full Text] [Related]  

  • 5. FDA-approved drug screening in patient-derived organoids demonstrates potential of drug repurposing for rare cystic fibrosis genotypes.
    de Poel E; Spelier S; Hagemeijer MC; van Mourik P; Suen SWF; Vonk AM; Brunsveld JE; Ithakisiou GN; Kruisselbrink E; Oppelaar H; Berkers G; de Winter de Groot KM; Heida-Michel S; Jans SR; van Panhuis H; Bakker M; van der Meer R; Roukema J; Dompeling E; Weersink EJM; Koppelman GH; Blaazer AR; Muijlwijk-Koezen JE; van der Ent CK; Beekman JM
    J Cyst Fibros; 2023 May; 22(3):548-559. PubMed ID: 37147251
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cystic Fibrosis Transmembrane Conductance Regulator Modulator Therapy: A Review for the Otolaryngologist.
    Lee SE; Farzal Z; Daniels MLA; Thorp BD; Zanation AM; Senior BA; Ebert CS; Kimple AJ
    Am J Rhinol Allergy; 2020 Jul; 34(4):573-580. PubMed ID: 32168995
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lung Inflammatory Genes in Cystic Fibrosis and Their Relevance to Cystic Fibrosis Transmembrane Conductance Regulator Modulator Therapies.
    Carbone A; Vitullo P; Di Gioia S; Conese M
    Genes (Basel); 2023 Oct; 14(10):. PubMed ID: 37895314
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Advanced Cystic Fibrosis Lung Disease and Lung Transplantation in the Era of Cystic Fibrosis Transmembrane Conductance Regulator Modulators.
    O'Carroll M
    Semin Respir Crit Care Med; 2023 Apr; 44(2):260-268. PubMed ID: 36893762
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Correctors (specific therapies for class II CFTR mutations) for cystic fibrosis.
    Southern KW; Patel S; Sinha IP; Nevitt SJ
    Cochrane Database Syst Rev; 2018 Aug; 8(8):CD010966. PubMed ID: 30070364
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The revolution of personalized pharmacotherapies for cystic fibrosis: what does the future hold?
    Oliver KE; Carlon MS; Pedemonte N; Lopes-Pacheco M
    Expert Opin Pharmacother; 2023; 24(14):1545-1565. PubMed ID: 37379072
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Airway clearance after highly effective CFTR modulators: Normalizing life and reducing treatment burden.
    Goetz DM; Frederick CK; Perez G; Borowitz D
    Pediatr Pulmonol; 2023 Aug; 58(8):2375-2380. PubMed ID: 37232336
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Review of CFTR modulators 2020.
    Goetz DM; Savant AP
    Pediatr Pulmonol; 2021 Dec; 56(12):3595-3606. PubMed ID: 34407318
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nontuberculous Mycobacteria in Cystic Fibrosis in the Era of Cystic Fibrosis Transmembrane Regulator Modulators.
    Burke A; Thomson RM; Wainwright CE; Bell SC
    Semin Respir Crit Care Med; 2023 Apr; 44(2):287-296. PubMed ID: 36649736
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Effect of CFTR Modulators on Airway Infection in Cystic Fibrosis.
    Harvey C; Weldon S; Elborn S; Downey DG; Taggart C
    Int J Mol Sci; 2022 Mar; 23(7):. PubMed ID: 35408875
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tezacaftor/Ivacaftor therapy has negligible effects on the cystic fibrosis gut microbiome.
    Marsh R; Dos Santos C; Hanson L; Ng C; Major G; Smyth AR; Rivett D; van der Gast C
    Microbiol Spectr; 2023 Aug; 11(5):e0117523. PubMed ID: 37607068
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Improvement of lipid and lipoprotein profiles in children and adolescents with cystic fibrosis on CFTR modulator therapy.
    Yuzyuk T; McDonald CM; Zuromski LM; De Biase I; Johnson L; Williams N; Meihls S; Asfour F
    J Cyst Fibros; 2023 Nov; 22(6):1027-1035. PubMed ID: 37453889
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Elevated Levels of Toxic Bile Acids in Serum of Cystic Fibrosis Patients with
    Tabori H; Schneider J; Lüth S; Zagoya C; Barucha A; Lehmann T; Kauf E; Barth A; Mainz JG
    Int J Mol Sci; 2022 Oct; 23(20):. PubMed ID: 36293293
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A new era for people with cystic fibrosis.
    Bierlaagh MC; Muilwijk D; Beekman JM; van der Ent CK
    Eur J Pediatr; 2021 Sep; 180(9):2731-2739. PubMed ID: 34213646
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CFTR modulator therapy alters plasma sphingolipid profiles in people with cystic fibrosis.
    Westhölter D; Schumacher F; Wülfinghoff N; Sutharsan S; Strassburg S; Kleuser B; Horn PA; Reuter S; Gulbins E; Taube C; Welsner M
    J Cyst Fibros; 2022 Jul; 21(4):713-720. PubMed ID: 35168870
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Small molecule modulators of cystic fibrosis transmembrane conductance regulator (CFTR): Structure, classification, and mechanisms.
    Cao L; Wu Y; Gong Y; Zhou Q
    Eur J Med Chem; 2024 Feb; 265():116120. PubMed ID: 38194776
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.